Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9126MR)

This product GTTS-WQ9126MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9126MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ747MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ9798MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ4439MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ3874MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ4168MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ13805MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ9219MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ11626MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW